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ABSTRACT
Background: Melanoma is the most frequent cancer in the canine oral cavity. It shows an aggressive behavior, character-
ized by rapid and invasive growth and high metastatic potential. Metastasis is seen in more than 80% of dogs at time of 
death. Adjuvant therapy should be recommended because of potential recurrence and metastasis. Oral melanoma has a poor 
prognosis even when adjuvant treatments are used. There are some treatment options, but the high death rate due to the 
disease is still a challenge. The aim of this study was to assess the overall survival of dogs diagnosed with oral melanoma 
and treated with adjuvant chemotherapy and immunotherapy. 
Materials, Methods & Results: A retrospective analysis was carried out in 20 dogs with oral melanocytic or amelanocytic 
melanomas. Cases were staged according to a modified World Health Organization clinical staging system for canine oral 
malignant melanoma. Tumor size (T1: < 2 cm; T2: 2 - 4 cm; T3: > 4 cm), regional metastasis (N0: no metastasis; N1: 
metastasis) and presence of distant metastasis (M0: no metastasis; M1: metastasis) are evaluated. Then, cases were divided 
into 4 stages: I (T1 N0 M0), II (T2 N0 M0), III (T3 N0-1 M0, Tx N1 M0) and IV (Tx Nx M1). Diagnoses were confirmed 
with histopathological exam and immunohistochemistry (IHC) when necessary. In poorly differentiated neoplasms, IHC was 
performed at the request of the submitting veterinarian using specific markers PNL-2 and Melan-A. Animals were divided 
into 2 groups: dogs submitted to surgery alone were included in group 1 (G1); dogs submitted to surgery associated with 
adjuvant chemotherapy with four 21-day cycles of carboplatin (300 mg/m2) and immunotherapy with six 7-day cycles of 
interferon-α (3 x 106 IU/m2) were included in group 2 (G2). Twenty dogs diagnosed with oral melanoma were evaluated: 
3 were included in G1 and 17 in G2. Considering clinical staging of the dogs: 7 stage II, 12 stage III and only 1 stage IV. 
There was no stage I patients. In poorly differentiated neoplasias, IHC was performed at the request of the submitting 
veterinarian using specific markers PNL-2 and Melan-A. Patient follow-up was obtained through the evaluation of patient 
records and telephone interviews with owners. The overall survival time (OS) was defined by the period (in days) between 
the date of surgical excision and the death caused by the disease. Median overall survival time was 86 days for animals in 
G1 and 894 days for animals in G2 (P = 0.01). 
Discussion: Carboplatin was considered an appropriate cytostatic drug to treat microscopic disease in oral melanoma. INF-α 
was chosen for immunotherapy in this study because it promotes immune system stimulation associated with an indirect 
antiproliferative effect on neoplastic cells. The association of INF-α and carboplatin resulted in a significant increase in 
overall survival, when compared to the literature, suggesting that association of chemotherapy and immunomodulation is 
an important strategy in the treatment of canine oral melanoma. Controlled prospective randomized trials are necessary 
to confirm the benefits of chemotherapy and immunotherapy association to treat canine oral melanoma. Adjuvant therapy 
with chemotherapy and immunotherapy was considered effective to increase overall survival and maintained quality of 
life of dogs diagnosed with oral melanoma. 
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INTRODUCTION
Melanoma is the most frequent cancer in the 
canine oral cavity. It shows an aggressive behavior, 
characterized by rapid and invasive growth and high 
metastatic potential to regional lymph nodes, lungs, 
and other [13,17]. Adjuvant therapy should be recom-
mended because of potential recurrence and metastasis 
[18], but the high death rate due to the disease is still 
a challenge [17]. Oral melanoma has a poor prognosis 
even when adjuvant treatments are used [17]. Treatment 
protocols with cytostatic drugs and immunotherapies are 
being developed for humans and animals to interfere 
with disease progression [1]. Adjuvant treatment for 
oral melanoma include chemotherapy, radiotherapy, 
electrochemotherapy [14,19] and immunotherapy, 
such as DNA xenogeneic vaccine [21]. The usage of 
immunomodulators to treat oral melanoma is promis-
ing, and dogs are a study model for human treatment 
[3,14]. Autologous tumor cell vaccines, allogeneic cell 
vaccines, canine dendritic cell vaccines with melano-
somic differentiating antigens and immunostimulatory 
such as interleukine-2 (IL-2) and tumor necrosis factor 
alpha (TNF-α) are used as immunotherapy for canine 
melanomas [14, 23]. Alpha interferon (INF-α) has been 
used in the treatment of other diseases but has not been 
reported in the treatment of canine oral melanoma [1].
The aim of this study was to assess the overall 
survival of dogs diagnosed with oral melanoma and 




A retrospective analysis was carried out in 
20 dogs with oral melanocytic or amelanocytic mela-
nomas admitted to the Federal University of Minas 
Gerais (UFMG), Belo Horizonte, Brazil. Animals were 
divided into 2 groups according to 2 different proto-
cols: 3 dogs submitted only to surgical excision of the 
neoplasm were included in group 1 (G1), and; 17 dogs 
submitted to surgical excision associated with adjuvant 
therapy using four 21-day cycles of carboplatin at 
300 mg/ m2 [EV, B - Platin®, injective]¹ and six 7-day 
cycles of INF-α at 3x106 IU/m2 [IM, Alfainterferona 
2a Humano Recombinante, injective]² were included in 
group 2 (G2). In case of suspected regional metastasis, 
cytology and lymph node removal were performed, 
and distant metastasis were diagnosed through thoracic 
radiographs. The animals treated only with surgery, 
due to the refusal of chemotherapy treatment by the 
responsible. Cases were staged according to a modified 
World Health Organization clinical staging system for 
canine oral malignant melanoma. Tumor size (T1: < 2 
cm; T2: 2-4c m; T3: > 4 cm), regional metastasis (N0: 
no metastasis; N1: metastasis) and presence of distant 
metastasis (M0: no metastasis; M1: metastasis) are 
evaluated. Then, cases were divided into 4 stages: I 
(T1N0M0), II (T2N0M0), III (T3N0-1M0, TxN1M0) 
and IV (TxNxM1) [3]. 
Histopathological and Immunohistochemistry evaluation
Diagnoses were confirmed with histopatho-
logical exam and IHC when necessary. The tumor 
samples were collected in a surgical procedure, fixed 
for 48 h in 10% buffered formaldehyde and wrapped 
in paraffin. Then, 4 μm histological sections were 
performed and stained with hematoxylin and eosin³ 
(H&E). In poorly differentiated neoplasias, IHC was 
performed at the request of the submitting veterinarian 
using specific markers PNL-24 and Melan-A5. The 4 μm 
sections were cut from melanoma samples, mounted 
on gelatin slides, dewaxed, and rehydrated, for im-
munohistochemical analysis. Staining was obtained 
according to the method of reaction of the peroxidase 
with the secondary antibody (Novolink Polymer Detec-
tion System)6. Antigenic recovery was carried out by 
incubating, for 20 min, in Citrate pH 6.0 target recovery 
solution (Dako Cytomation)5, 2 min in pressurized 
moist heat, in a Pascal® pressure cooker7 at 125°C, 
and cooling to temperature environment. Endogenous 
peroxidase was blocked by double incubation for 10 
min in 3% hydrogen peroxide in methanol solution. 
Through incubation, for 20 min in the Ready to Use 
reagent without whey protein block5, non-specific 
binding sites of endogenous proteins were blocked. 
Sections were incubated, for 16 h at room temperature, 
with primary antibodies with specific dilutions for 
each, followed by HRP polymer (Novolink polymer 
detection system)6 and 1-min incubation with chro-
mogen 3′3-diaminobenzidine (DAB system)5. Finally, 
the slides were contrasted with the Giemsa dye, in the 
dilution 1: 5, for 30 min and washed with hydrochloric 
acid, dilution 1: 100, absolute alcohol and isopropyl 
alcohol, respectively. Then, the melanin pigment be-
comes greenish, different from the brown hue found 
in the DAB / primary antibody chromogen reaction. 
3
                                                                                                           G.E. Lavalle, C.E.T. Caires, S.V. Teixeira, R.M.C. Cunha & R.A. Carneiro. 2021. Treatment of Canine Oral Melanoma with Adjuvant 
Chemotherapy and Immunotherapy.                                                                                                                  Acta Scientiae Veterinariae. 49: 1808.
The negative control was done by incubating the slides 
with antibody diluent (Antibody Diluent with Bot-
tom Reducing Components)5. Positive controls were 
analyzed in non-neoplastic areas of the samples [22]. 
Statistical analysis
Patient follow-up was obtained through the 
evaluation of patient records and telephone interviews 
with owners. The overall survival time (OS) was de-
fined by the period (in days) between the date of surgi-
cal excision and the death caused by the disease. Deaths 
from unknown causes or causes unrelated to the tumor 
were censored. For OS evaluation, univariate analysis 
was used (Kaplan-Meier estimated survival curves). 
They were considered statistically significant when 
P-values < 0.05 by the log-rank test (Cox-Mantel). 
Median survival was determined by the period in which 
50% of patients in a group came to death.
RESULTS
Twenty dogs diagnosed with oral melanoma 
were evaluated: 3 (15%) were included in G1 and 17 
(85%) in G2. Considering clinical staging: 7 (35%) 
stage II, 12 (60%) stage III and only 1 (5%) in stage 
IV. There was no stage I patients. 
According to the histomorphology classifica-
tion, 4 (20%) of tumors were amelanocytic and 16 (80%) 
were melanocytic melanomas. A significant increase 
in overall survival was associated with the proposed 
adjuvant therapy. Median overall survival time was 86 
days for G1 and 894 days for G2 (P = 0.01; Figure 1).
Figura 1. Overall survival for surgery (G1) and surgery associated with 
adjuvant therapy (G2) dogs.
DISCUSSION
Canine oral melanoma metastasis can be seen 
in 70% of enlarged lymph nodes and in 40% of clini-
cally normal lymph nodes at diagnosis [19,23]. This 
shows that most diagnoses are late, as seen in the pres-
ent study. The low frequency with which tutors check 
their pet´s mouth and delay in seeking veterinary care 
could partially justify the frequent late diagnosis. A 
study was demonstrated an overall survival of 65 days 
for untreated dogs and 86.5 days for dogstreated with 
surgery alone, suggesting that surgery alone does not 
significantly improve survival and that therapeutic 
complementation may be important in canine oral 
melanomas [11].  
Local and systemic treatments are essential to 
adequately treat canine oral melanoma [1,7,15,17,20]. 
One previous study failed to demonstrate improve-
ment in overall survival when adjuvant therapies were 
associated with surgical excision of the neoplasm [7]. 
Carboplatin was considered an appropriate cytostatic 
drug to treat microscopic disease in oral melanoma 
[10, 17]. A study compared adjuvant radiotherapy 
and carboplatin, and the drug was considered as the 
adjuvant treatment of choice by the authors [10]. Only 
mild to moderate side effects (myelosuppression) 
were seen throughout the study, and it was considered 
a safe drug. 
Radiotherapy is rarely used in Brazil due to 
high cost and it is only available in two states, but it 
can also be considered a treatment option for inoper-
able tumors, tumors that did not have clean surgical 
margins and for animals with lymph node metastasis, 
without distant metastasis [4,9,12]. In 2012, was 
reported similar overall survival and disease-free 
interval with usage of adjuvant carboplatin [10]. 
INF-α was chosen for immunotherapy in this study 
because it promotes immune system stimulation as-
sociated with an indirect antiproliferative effect on 
neoplastic cells, possibly resulting in an anticancer 
response [1,6,12]. Median overall survival of dogs in 
G2 was approximately 2.5 years, far superior to dogs 
in G1 (86.5 days). An overall survival of 165 days 
for animals treated with surgery and carboplatin was 
described, while was described an overall survival of 
477 days and 510 days for stage II and III animals 
treated with Oncept vaccine as adjuvant therapy 
[8,15,16,21]. Therefore, the association of INF-α 
and carboplatin resulted in a significant increase 
in overall survival, when compared to the cited lit-
erature, suggesting that association of chemotherapy 
and immunomodulation is an important strategy in 
the treatment of canine oral melanoma. It should be 
noted that Oncept vaccine is not available in Brazil.
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Severe side effects were not seen during treat-
ment with carboplatin and INF-α. Mild to moderate 
myelosuppression was related with usage of carbopla-
tin, which was evaluated with complete blood counts 
performed at the drug´s nadir. No side effects were 
attributed to INF-α.
Controlled prospective randomized trials are 
necessary to confirm the benefits of chemotherapy 
and immunotherapy association to treat canine oral 
melanoma.
CONCLUSION
Therapeutic complementation with chemo-
therapy and immunotherapy was associated with 
an increase in overall survival, with maintenance 
of quality of life of dogs diagnosed with oral mela-
noma. The authors believe that multimodal therapy 
has a significant beneficial effect in the treatment 
of canine oral melanoma and its usage should be 
encouraged.
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